Clasificación en acciones
#27154
Cleveland BioLabs, Inc. functions as a biopharmaceutical firm, specializing in... Cleveland BioLabs, Inc. functions as a biopharmaceutical firm, specializing in the discovery and advancement of therapeutic drugs. Based in Buffalo, New York, the organization maintains a modest workforce of 15 full-time employees. Its primary objective involves pioneering methods to stimulate the body's immune defenses to tackle significant medical challenges. A core component of its work is a platform utilizing Toll-like immune receptor activators, which demonstrates utility in both alleviating radiation-induced damage and in the field of immuno-oncology. The most advanced therapeutic candidate in its pipeline is Entolimod, an immune-stimulating compound currently under development as a protective measure against radiation exposure and as an immunotherapy for various cancers and other indications. The company's portfolio also encompasses other promising products, including CBLB612, Mobilan, and CBL0137. CBLB612 is formulated from a natural stimulant that targets a specific component of the innate immune system: the heterodimeric receptor formed by toll-like receptors 2 (TLR2) and 6 (TLR6). Mobilan is a recombinant, non-replicating adenovirus engineered to induce the expression of TLR5 and its corresponding agonistic ligand. Lastly, CBL0137 is a small molecule characterized by a multi-faceted mechanism of action, suggesting its potential effectiveness across diverse forms of cancer.
Precio por acción
$3.17
Última sincronización: 2021-08-31
Capitalización bursátil
$34.83M
Comercio Cytocom, Inc. (CBLI)
Ganancias de Cytocom, Inc. (CBLI)
Ganancias en 2026 TTM: 0
Secondo gli ultimi rapporti finanziari di Cytocom, Inc., gli utili attuali della società sono 0. Nel 2026, la società ha registrato un utile di 0, igual a agli utili del 2026, che erano di 0. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Cytocom, Inc. desde 2026 hasta 2026
Ganancias al final de cada año
| Año |
Ganancias |
Cambiar |
|
Not enough data for the provided dates. |
Ganancias de empresas similares o competidoras
| Empresa |
Ganancias |
Diferencia de ganancias |
País |
|
|
$5.27B |
-
|
US
|
|
|
$-3.09B |
-
|
US
|
|
|
$1.95B |
-
|
NL
|
|
|
$1.61B |
-
|
AU
|
|
|
- |
-
|
CH
|
